This bill reauthorizes the Accelerating Access to Critical Therapies for ALS Act through 2031 while enhancing grant oversight, refining clinical trial definitions, and mandating updated FDA and GAO reporting on neurodegenerative disease research.
Mike Quigley
Representative
IL-5
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends vital funding and research support for ALS therapies through 2031. This legislation enhances grant oversight, clarifies clinical trial definitions, and mandates updated FDA action plans to improve the development of treatments for ALS and other rare neurodegenerative diseases.
ALS Research Funding Extended to 2031: New FDA Accountability and Clinical Trial Rules Set to Kick In
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 ensures that the fight against neurodegenerative diseases doesn't hit a financial wall. By extending the original 2021 Act for another five years—moving the expiration date from 2026 to 2031—this bill secures the pipeline for research grants and federal support. It isn't just about keeping the lights on, though; it introduces new layers of oversight to make sure the money is actually moving the needle on treatments for patients. For families dealing with an ALS diagnosis, this means the specialized research programs they rely on have a guaranteed runway for the next several years.
Keeping Tabs on the Lab
Section 3 of the bill changes how the government handles grant renewals. If a pharmaceutical company or research lab wants to keep their funding for an investigational drug, the Secretary of Health and Human Services (HHS) now has to look under the hood. Specifically, the Secretary must review interim clinical trial data and patient enrollment numbers before cutting another check. Think of it like a performance review for a major construction project: the bill requires the manufacturer to share data to prove that the trial is actually progressing and recruiting the people it promised to help. This prevents funding from being tied up in stagnant projects that aren't moving toward a cure.
Widening the Net for New Treatments
The bill also gets technical with definitions to help more research qualify for support. It clarifies that 'phase 3' clinical trials now include combined phase 2/3 trials and even planned trials that haven't started enrolling people yet. For a biotech startup or a university research team, this is a big deal because it allows them to apply for grants earlier in the process. By broadening the definition, the bill aims to reduce the 'valley of death' where promising medical ideas often fail because they can't secure the funding needed to jump from small-scale testing to large-scale human trials.
A Roadmap for Rare Diseases
Under Section 4, the FDA is being put on a deadline to show its work. Within one year, the Commissioner must publish an updated five-year action plan that outlines exactly how they will handle rare neurodegenerative diseases. This isn't just a vague to-do list; the bill requires the FDA to specify the resources needed and explain how they will coordinate with communities outside of just the ALS space. It also forces a look back at the 2022 Action Plan to see what actually worked and what didn't. For the average person, this means more transparency into how a massive agency like the FDA prioritizes the diseases that don't always get the most headlines but have the most devastating impacts on families.